Novo Nordisk

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk's newest diabetes treatment, an oral drug called Rybelsus, won't immediately gouge another medicine from pharmaceutical company Eli Lilly. Both are GLP-1 receptor agonists.

What The Price Tag Says About Novo Nordisk's Newest Diabetes Drug

Novo Nordisk's (NVO) semaglutide in tablet form gets FDA nod as an adjunct to diet and exercise to improve glycaemic control in adults with type II diabetes mellitus.

Novo Nordisk's Semaglutide in Tablet Form Gets FDA Approval

AstraZeneca

Eli Lilly

Here's what investors need to know about a new injection-free, non-insulin treatment for type 2 diabetes.

Meet the Revolutionary New Diabetes Drug You've Probably Never Heard Of

On Friday, NVO received approval of oral semaglutide as Rybelsus.

Novo Nordisk: Rybelsus Approved, And The Stock May Finally Go Up

AbbVie

Gilead Sciences

Sanofi

Patents and monopolies don’t always go hand in hand.

An Investor's Guide to Disrupting Drugmakers

Novo Nordisk stock popped Tuesday after an analyst suggested the pharmaceutical company's oral diabetes treatment, semaglutide, could swipe share from Eli Lilly's rival drug, Trulicity.
The post How This Pharma Stock Could Knock Eli Lilly Off Its Diabetes Pedestal appeared first on Investor's Business Daily.

How This Pharma Stock Could Knock Eli Lilly Off Its Diabetes Pedestal

Medtronic

This collaboration is expected to boost Medtronic's (MDT) diabetes management portfolio.

Medtronic Collaborates With Novo Nordisk for Diabetes Care

Canadian National Railway Company

Diageo

Roche Holding AG

The dividend-growth strategy works for both domestic and foreign markets.

5 High-Quality Dividend Contenders From Overseas To Diversify Your Dividend Growth Portfolio

Merck

Pfizer

Shares of pharmaceutical companies toppled Tuesday on reports the House of Representatives will release a plan that allows the federal government to negotiate drug prices in Medicare.

Pharma Stocks Hammered As House Proposal Aims To Slash Drug Prices

Novo Nodisk is introducing its own discounted insulin "follow-on brands" to NovoLog and NovoMix.

Novo Nordisk Joins Insulin Discount Party, But Prices Still Unlikely To Fall

Novo Nordisk said on Friday it would offer cheaper insulin to some U.S. diabetics in response to intense criticism over the high price of the medication and following similar moves by rivals Sanofi and Eli Lilly.

Novo Nordisk to cut insulin prices for some U.S. diabetics

Renewable Energy Group

These two businesses could receive a big boost this month if certain events fall in their favor.

2 Stocks to Watch in September

Does Novo Nordisk (NVO) have what it takes to be a top stock pick for momentum investors? Let's find out.

Novo Nordisk (NVO) Is Up 2.77% in One Week: What You Should Know

Novo Nordisk is seeing a long runway ahead, thanks to the megatrends in diabetes and obesity globally.

Novo Nordisk: A Secular Growth Engine

Mylan

News of Novo Nordisk suing Mylan is spreading as the two companies prepare for a legal battle over a generic version of Victoza.
The post Novo Nordisk Suing Mylan Over Generic Victoza Drug appeared first on InvestorPlace.

Novo Nordisk Suing Mylan Over Generic Victoza Drug

Novo Nordisk (NVO) receives EC approval for its fast-acting insulin aspart, Fiasp, for the treatment of diabetes in adolescents and children aged one year or older.

Novo Nordisk's Fiasp Gets EC Approval for Label Expansion

Novo Nordisk  said on Thursday it has filed litigation in a Delaware district court against Mylan  aimed at blocking its attempt to market a generic version of the Danish insulin maker's drug Victoza.

Denmark's Novo Nordisk files lawsuit against Mylan over patent

Infosys

Intel

Snap-on

Texas Instruments

High dividend yield stocks include 2 semiconductor manufacturers.

5 Dividend Growth Stocks to Consider in Light of Falling Treasury Yields

The second quarter wasn't too shabby either.

Novo Nordisk Waits for Its Next Launch

Novo Nordisk (NVO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Earnings Season Could Be Great for Novo Nordisk (NVO)

Lockheed Martin

Starbucks

The following stocks have performed very well over the past month, year and three years.

Will These 3 Good Performers Beat the Market?

Novo Nordisk A/S (NVO) CEO Lars Fruergaard Jorgensen on Q2 2019 Results - Earnings Call Transcript

Novo Nordisk (NVO) beats earnings and sales estimates in the second quarter of 2019.

Novo Nordisk (NVO) Q2 Earnings & Revenues Beat Estimates

Led by pharmaceuticals including Novo Nordisk and Merck KGaA MRK, +2.38% , European stocks traded higher on Thursday, with the Stoxx 600 Europe SXXP, +0.71% rising 0.8% in early action.

Europe stocks climb in early action, led by pharmas

Novo Nordisk said on Tuesday it had bought a factory in North Carolina that would assist in manufacturing and packaging its new once-daily pill for treating type 2 diabetes.

News for Novo Nordisk Stock (NVO)